Date: 25.11.2025

Direct healthcare-professional communication (DHPC)

Dear Health Care Professionals,

Bioremedy in agreement with Saudi Food and Drug Administration (SFDA) in Kingdom of Saudi Arabia would like to inform you of important safety information regarding the use of **Hyaluronidase**:

We would like to inform you that **Hyaluronidase (Huons)** from the batch listed below has been distributed with **labeling information in Japanese** to meet the shortage in this product. Hence, to ensure safe and effective use, we are sharing the batch details for your reference and will be providing the English package insert:

Product Name: Hyaluronidase (Huons)
Batch Number (Lot): 102302
Expiry Date: 25.04.2026

Please review the information above and ensure that relevant healthcare professionals within your facility are aware. The **English-language package insert** will be attached for your reference.

Should you have any questions or require further clarification, please do not hesitate to contact us.

Call for reporting

As a reminder, there is a need to report any suspected adverse reactions in accordance with the

national spontaneous reporting system via the following contacts

The Marketing Authorisation Holder (MAH), Bioremedy Pharma:

- E-mail: br@bioremedypharma.com

The National Pharmacovigilance Centre (NPC):

Date: 25.11.2025

- SFDA Call Center: 19999
- E-mail: npc.drug@sfda.gov.sa
- Website: https://ade.sfda.gov.sa/.

Please ensure to report the product strength and batch details as well.

Company contact point

For further enquiries concerning this information, please contact

t: +966564377880 and norah@bioremedypharma.com

Thank you for your attention.

Title: QPPV

Name: Norah Alrshoud

Phone: 0564377880

HYALASE 1500 IU Injcetion

ETC

【Ingredient information】 1500 IU of hyaluronidase

【Appearance】

Colorless and transparent vial containing freeze-dried white powder

【Efficacy/Effect】

- Increased penetration by subcutaneous injection, intramuscular injection, local anesthetic, and subcutaneous injection
- Promote reabsorption of excess body fluids and blood in tissues

【Dosage】

Adults, children and the elderly

1. For subcutaneous injection (mass subcutaneous injection)
   Dissolve 1,500 I.U. of hyaluronidase in 1 mL of water for injection or saline solution and inject it into the affected area before starting subcutaneous injection, or inject it into the tube 2 cm above the injection needle when starting the injection. 1,500 I.U. of this drug is suitable for administration of 500 ~ 1,000 mL of infusion. In children and the elderly, the rate and total dose of infusions should be carefully controlled, and especially, if there is a renal impairment, be careful not to become excessively watery.
2. When injected subcutaneously or intramuscularly
   Dissolve 1,500 I.U. of this drug directly into the injection solution to be administered.
3. Local anesthetic
   Dissolve 1,500 I.U. of this drug in the local anesthetic injection solution to be administered. For ophthalmic use, a concentration of 15 I.U. per mL is recommended.
4. Extravasation
   In cases of diffusion rather than local cases, as soon as possible after extravasation appears, dissolve 1,500 I.U. of this drug in 1 mL of water for injection or physiological saline and infiltrate the lesion site.
5. Hematoma
   Dissolve 1,500 I.U. of this drug in 1 mL of water for injection or physiological saline injection and infiltrate the affected area.
   Dissolve this drug in the injection solution to be administered with about 1 mL of water for injection immediately before use.
   Subcutaneous injection solution should be isotonic with the extracellular fluid in the body. This drug can be combined with commonly used infusions. An example of using physiological saline solution, 0.18% sodium chloride 4% glucose, 0.45% sodium chloride 2.5% glucose, and 5% glucose injection solution for massive subcutaneous injection has been reported.
   Potassium is administered at 34 mmol/L in isotonic glucose or physiological saline.
   Infusions containing electrolytes are more suitable than infusions without electrolytes, and should not be administered too quickly. This drug is used in admixture with morphine, diamorphine, hydromorphine, chlorpromazine, metoclopramide, promazine, dexamethasone, a local anesthetic and epinephrine.

【Usage Precautions】

1. Warning

Glass shards may be mixed in the ampoule injection when cutting the container, which may cause an adverse reaction, so cut it carefully to minimize the mixing of glass shards when using it, but be especially careful when using it in children and the elderly (limited to the glass ampoule injection).

2. Do not administer to the following patients (cases).

1) Patients with a history of shock to this drug
2) Patients with hypersensitivity to this drug or bovine protein
3) Edema caused by a bite or sting
4) Infectious or cancerous site or its vicinity (Can expand the cancer lesion and infected site by increasing tissue permeability.)
5) Anesthesia for premature delivery of unknown cause
6) Patients with congenital heart defects, patients with venous congestion
7) Patients whose serum protein level is 5.5 g% or less

8) lactating women

3. Administer with caution to the following patients.

Patients with a history of drug hypersensitivity

4. Adverse reactions

1) Hypersensitivity reaction: Rarely, a severe allergic reaction accompanied by shock may occur.
2) Administration site: Rarely, local irritation, redness, pain, infection spread, bleeding and bruising may occur. Edema has been reported in connection with mass subcutaneous injection.
3) Others: Rarely, fever, tooth agitation, and menstruation may occur.
4) As a result of analysis and evaluation of serious adverse events collected after domestic marketing, the confirmed adverse events are as follows. However, this does not mean that a causal relationship has been proven between the ingredient and the following adverse events.

• Immune system: anaphylactic reaction

5. General caution

1) Even a very small amount can cause an allergic reaction. In order to predict the reaction such as hypersensitivity reaction, it is desirable to ask enough questions and conduct a skin reaction test in advance.
2) In the case of driving or operating dangerous machinery during the treatment period, act carefully under the judgment of the doctor.

6. Interaction

1) Heavy metal salts act as antagonists of this drug.
2) When combined with preparations containing salicylic acid derivatives, the reabsorption promoting effect of this drug may be reduced.
3) Do not consume alcohol during or immediately after administration of this drug as it may enhance the action of alcohol.
4) In case of overdose of this drug, the efficacy of locally applied drugs such as local anesthetics may be reduced.

7. Administration to pregnant and lactating women

1) Since the safety of administration during pregnancy has not been established, it should be administered only when it is judged that the therapeutic benefit outweighs the risk to pregnant women or women who may be pregnant.
2) It is not known whether this drug is excreted in breast milk, so it should not be administered to nursing mothers.

8. Administration to the elderly

In general, elderly people have reduced physiological function, so be careful, such as reducing weight.

9. Treatment in case of overdose

1) Symptoms: Nausea, flushing, urticaria, rapid pulse (tachycardia), dyspnea, shock, respiratory arrest, etc. may appear.
2) Treatment: Stop taking this drug and administer an antihistamine if skin symptoms such as flushing or hives appear. If rapid pulse (tachycardia) occurs, intravenous corticosteroids may be administered. In case of shock, epinephrine, oxygen supply, intravenous administration of corticosteroids, and airway maintenance should be administered. If respiratory arrest occurs, CPR should be performed.

10. APPLICATION PRECAUTIONS

1) Use immediately after preparing a solution.
2) Do not administer directly into the cornea or joint as it may cause edema.
3) Do not inject intravenously.
4) Although this drug is physically inappropriate to mix with heparin and epinephrine (it becomes cloudy), it can be used without any problem in clinical practice by mixing it with a very low concentration of epinephrine. This drug should not be combined with furosemide, benzodiazepines, phenytoin, chondroitin B sulfate containing sulfonate surfactants, or bile salts.
5) This drug is not used to promote diffusion or absorption of alpha blockers or dopamine drugs.

【Storage】 Sealed container, stored at room temperature below 25℃

【Packing】 10 Vials / Pack /

【Manufacturer】 Huons Address: 253C-902 Pangyo-ro Bundang-gu, Sungnam Kyunggi-do (Sampyeong-dong, InnoValley), 13486, Korea / Customer consultation: +82-(0)80-447-4700